Trials / No Longer Available
No Longer AvailableNCT04714086
Expanded Access Program for Avapritinib
Expanded Access Program (EAP) for Avapritinib
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Blueprint Medicines Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This record comprises the currently available Expanded Access Programs (EAP) for avapritinib (BLU-285): 1\) A Post Trial Access (PTA) program to provide continued access to treatment with avapritinib to BLU-285-1107 participants with solid tumors who are unable to access commercially available avapritinib after trial BLU-285-1107 (NCT04908176) has ended.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avapritinib | Avapritinib will be administered orally at 300 mg QD. |
Timeline
- First posted
- 2021-01-19
- Last updated
- 2024-10-24
Source: ClinicalTrials.gov record NCT04714086. Inclusion in this directory is not an endorsement.